TBA (last known deadline was October 15, 2012)
The MRA is soliciting proposals that address the gap in translational science, i.e., turning scientific discoveries into tools and/or treatments for high risk individuals and melanoma patients. Successful proposals will offer the potential for translational development that could lead to high impact near-term clinical application in melanoma detection, prevention, diagnosis, staging, or treatment.
Multidisciplinary teams of two or more PIs will receive up to $1 million total over 2 to 3 years, to support projects with the potential to lead to transforming advances in prevention, early detection, staging and/or treatment of melanoma. All PIs in the team share authority for scientific leadership. The designated Administrative PI is responsible for administrative leadership. New for the 2013 award cycle is the requirement that each team must include at least one Young Investigator as a co-investigator (see and comply with all Young Investigator eligibility criteria above), who will receive up to $75,000/year. The Research Plan may include one Pilot Study embedded as an aim or sub-aim, which articulates a clear hypothesis and translational goals but is not supported by extensive preliminary data. Suggested duration and scope of Pilot Studies is $50,000/year for 1-2 years.